{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-07-18&min-date=2019-06-03&answer.dateOfAnswer=2023-11-28&answer.answeringMemberPrinted=Andrew+Stephenson", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2019-07-18&min-date=2019-06-03&answer.dateOfAnswer=2023-11-28&answer.answeringMemberPrinted=Andrew+Stephenson", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-07-18&min-date=2019-06-03&answer.dateOfAnswer=2023-11-28&_metadata=all&answer.answeringMemberPrinted=Andrew+Stephenson", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-07-18&_page=0&min-date=2019-06-03&answer.dateOfAnswer=2023-11-28&answer.answeringMemberPrinted=Andrew+Stephenson", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-07-18&min-date=2019-06-03&answer.dateOfAnswer=2023-11-28&answer.answeringMemberPrinted=Andrew+Stephenson", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-07-18&min-date=2019-06-03&answer.dateOfAnswer=2023-11-28&answer.answeringMemberPrinted=Andrew+Stephenson", "items" : [{"_about" : "http://data.parliament.uk/resources/1672660", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1672660/answer", "answerText" : {"_value" : "
Medicine supply problems can occur for several reasons; for example, they can be due to manufacturing difficulties, regulatory problems, problems with the supply of raw materials, sudden demand spikes or from issues which are related to the distribution of the product.<\/p>
<\/p>
We have well-established processes for managing and mitigating medicine supply issues, which involve working with the pharmaceutical industry, the Medicines and Healthcare products Regulatory Agency, NHS England, the devolved governments and others operating in the supply chain to help ensure patients have access to the treatments they need.<\/p>
Disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, which are expected to resolve by the end of 2023 or in early 2024.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2023-11-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-11-28T10:10:31.66Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-11-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Attention Deficit Hyperactivity Disorder: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Answer of 22 November 2023 to Question 1712 on Attention Deficit Hyperactivity Disorder: Drugs, if she will make an assessment of the adequacy of her Department\u2019s processes to (a) manage and (b) mitigate problems in the supply of medicines used for the management of ADHD.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4698", "label" : {"_value" : "Biography information for Janet Daby"} } , "tablingMemberConstituency" : {"_value" : "Lewisham East"} , "tablingMemberPrinted" : [{"_value" : "Janet Daby"} ], "uin" : "3545"} , {"_about" : "http://data.parliament.uk/resources/1672750", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1672750/answer", "answerText" : {"_value" : "
The Department has not awarded a contract for a consultant to work on National Health Service productivity in 2023/24.<\/p>
However, the Government is ambitious for NHS productivity. That is why the Long Term Workforce Plan set out an ambition to achieve 1.5-2% average workforce productivity growth. We would expect the NHS to make best use of all options available, including potential use of consultancy support where there is an appropriate value for money case to do so, to understand the challenge and deliver on this ambition.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2023-11-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-11-28T10:09:36.247Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-11-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Productivity"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has awarded a contract for a consultant on the NHS review into productivity in the 2023-24 financial year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "tablingMemberConstituency" : {"_value" : "Bristol South"} , "tablingMemberPrinted" : [{"_value" : "Karin Smyth"} ], "uin" : "3499"} , {"_about" : "http://data.parliament.uk/resources/1672173", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1672173/answer", "answerText" : {"_value" : "
The essential medicines buffer stock program is no longer active and there are no stocks held under this. Some medicines that were previously held for COVID-19 preparedness, including midazolam 50 milligram/10 millilitre ampoules, are in the process of being transitioned into centralised stockholdings of countermeasures for broader emerging infectious disease and pandemic preparedness. Stocks of morphine 10 milligram/millilitre and 10 milligram/2 millilitre and fentanyl 500 microgram/10 millilitre remain, but will not be retained centrally. The countermeasures programme is informed by scientific and clinical assessment of the evidence base and is kept under review, building on lessons learned from COVID-19 and other outbreaks.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2023-11-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-11-28T12:34:09.38Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-11-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what stocks of (a) midazolam, (b) morphine and (c) fentanyl are held in (i) the essential medicines buffer stock and (ii) the UK stockpile of medicines for covid-19 preparedness.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4133", "label" : {"_value" : "Biography information for Andrew Bridgen"} } , "tablingMemberConstituency" : {"_value" : "North West Leicestershire"} , "tablingMemberPrinted" : [{"_value" : "Andrew Bridgen"} ], "uin" : "3233"} , {"_about" : "http://data.parliament.uk/resources/1672189", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1672189/answer", "answerText" : {"_value" : "
We do not hold the requested information centrally.<\/p>
The \u2018Financial assistance under section 40 of the National Health Service Act 2006\u2019 reports set out all funding that was provided to NHS trusts for each financial year and are published with the Department of Health and Social Care Annual Report and Accounts. However, this does not itemise the funding at the individual hospital and site level. The reports are available at the following link:<\/p>